Company intelligence / Profile preview

Shihezi Ansheng

Shihezi, Xinjiang, China

Ownership: Private
Development stage: Other

Overview

Shihezi Ansheng was an investor in Genor Biopharma, which developed monoclonal antibody biosimilars including GB221 (Herceptin biosimilar) approved for clinical trials in 2013, GB242 (Remicade biosimilar), GB232 (Humira biosimilar), and GB222 (Avastin biosimilar). Genor was being acquired by Walvax Biotechnology in a deal involving 58.08% from Shihezi Ansheng.[5]

Therapeutic areas: OncologyImmunology
Modalities: Monoclonal antibody
Industry: Investors

Beyond the preview

Go deeper on Shihezi Ansheng.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shihezi Ansheng.

Explore the full profile